Last reviewed · How we verify
EBGLYSS (LEBRIKIZUMAB-LBKZ)
EBGLYSS (generic name: LEBRIKIZUMAB-LBKZ) is a Interleukin-13 Antagonist [EPC] drug developed by ELI LILLY AND CO. It is currently FDA-approved.
At a glance
| Generic name | LEBRIKIZUMAB-LBKZ |
|---|---|
| Sponsor | ELI LILLY AND CO |
| Drug class | Interleukin-13 Antagonist [EPC] |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
- Conjunctivitis
- Injection site reactions
- Herpes zoster
Serious adverse events
- Eosinophilia (>5000 cells/mcL)
- Keratitis
Key clinical trials
- A European, Multicenter, Prospective Observational Phase IV Clinical Study to Assess the Impact of Lebrikizumab on Health-Related Well-Being and Control of Skin Manifestations in Patients With Moderat (N/A)
- A Phase 1, Randomized, Two-part, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity and Pharmacodynamics of LAD (Phase 1)
- A Phase IV, Non-randomized, Open-label Multinational Trial to Assess the Mechanism of Action for Lebrikizumab in Moderate-to-severe Atopic Dermatitis (Phase 4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EBGLYSS CI brief — competitive landscape report
- EBGLYSS updates RSS · CI watch RSS
- ELI LILLY AND CO portfolio CI
Frequently asked questions about EBGLYSS
What is EBGLYSS?
EBGLYSS (LEBRIKIZUMAB-LBKZ) is a Interleukin-13 Antagonist [EPC] drug developed by ELI LILLY AND CO.
Who makes EBGLYSS?
EBGLYSS is developed and marketed by ELI LILLY AND CO (see full ELI LILLY AND CO pipeline at /company/eli-lilly).
What is the generic name of EBGLYSS?
LEBRIKIZUMAB-LBKZ is the generic (nonproprietary) name of EBGLYSS.
What drug class is EBGLYSS in?
EBGLYSS belongs to the Interleukin-13 Antagonist [EPC] class. See all Interleukin-13 Antagonist [EPC] drugs at /class/interleukin-13-antagonist-epc.
What development phase is EBGLYSS in?
EBGLYSS is FDA-approved (marketed).
What are the side effects of EBGLYSS?
Common side effects of EBGLYSS include Conjunctivitis, Injection site reactions, Herpes zoster. Serious adverse events: Eosinophilia (>5000 cells/mcL), Keratitis.
Related
- Drug class: All Interleukin-13 Antagonist [EPC] drugs
- Manufacturer: ELI LILLY AND CO — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing